Fereshteh Shokri
Fereshteh Shokri has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Lopez-Rincon
Utrecht University, Utrecht, Netherlands
1 shared publication - Alireza Mashaghi
Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Faculty of Science, Leiden University, 2333 CC Leiden, The Netherlands
1 shared publication Anouar Ait Hoummad
Haagse Transvaal Bereidingsapotheek, The Hague, The Netherlands
1 shared publicationArjen J. Jansen
Faculty of Industrial Design Engineering, Delft University of Technology, Delft, The Netherlands
1 shared publicationArwin Ramcharan
Haagse Transvaal Bereidingsapotheek, The Hague, The Netherlands
1 shared publication- Carolina Medina-Gomez
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 23 May 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 110
On eco-friendliness and 3D printing of pharmaceuticals
- 23 May 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 110
On eco-friendliness and 3D printing of pharmaceuticals
- 22 January 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (1) , 1-11
3D Drug Printing by Semi-Solid Extrusion Through Reusable Cartridges: Usability Evaluation
- 22 January 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (1) , 1-11
3D Drug Printing by Semi-Solid Extrusion Through Reusable Cartridges: Usability Evaluation
- Open Access
Bi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Background: Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles. Methods: A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included. Results: Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control. Conclusions: This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.
Open AccessBi-Directional Interactions between Glucose-Lowering Medications and Gut Microbiome in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Background: Although common drugs for treating type 2 diabetes (T2D) are widely used, their therapeutic effects vary greatly. The interaction between the gut microbiome and glucose-lowering drugs is one of the main contributors to the variability in T2D progression and response to therapy. On the one hand, glucose-lowering drugs can alter gut microbiome components. On the other hand, specific gut microbiota can influence glycemic control as the therapeutic effects of these drugs. Therefore, this systematic review assesses the bi-directional relationships between common glucose-lowering drugs and gut microbiome profiles. Methods: A systematic search of Embase, Web of Science, PubMed, and Google Scholar databases was performed. Observational studies and randomised controlled trials (RCTs), published from inception to July 2023, comprising T2D patients and investigating bi-directional interactions between glucose-lowering drugs and gut microbiome, were included. Results: Summarised findings indicated that glucose-lowering drugs could increase metabolic-healthy promoting taxa (e.g., Bifidobacterium) and decrease harmful taxa (e.g., Bacteroides and Intestinibacter). Our findings also showed a significantly different abundance of gut microbiome taxa (e.g., Enterococcus faecium (i.e., E. faecium)) in T2D patients with poor compared to optimal glycemic control. Conclusions: This review provides evidence for glucose-lowering drug and gut microbiome interactions, highlighting the potential of gut microbiome modulators as co-adjuvants for T2D treatment.
- Open Access
- 27 January 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 155, 106584
Biochemical reaction network topology defines dose-dependent Drug–Drug interactions
- 27 January 2023
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 155, 106584
Open AccessBiochemical reaction network topology defines dose-dependent Drug–Drug interactions